CD8A and neoplasm: A randomized trial showed that neoadjuvant vaccination with tumor-cell lysate enabled to induce effector CD8 + T cell response in LGG patients’ peripheral blood and vaccine-reactive CD8 + T cells to migrate into the tumor microenvironment [29].